Marker Therapeutics, Inc. Forecast, price target & analysts
$1.02
7.27%
today
Nasdaq,
Apr 04, 10:00 pm CET
Marker Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Powered by
Marker Therapeutics, Inc. Classifications & Recommendation:
Buy
100%
Marker Therapeutics, Inc. Price Target
| Target Price | $8.17 |
| Price | $1.00 |
| Potential |
716.67%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Marker Therapeutics, Inc. 2026 .
The average Marker Therapeutics, Inc. target price is $8.17.
This is
716.67%
register free of charge
$12.50
1,150.00%
register free of charge
$4.00
300.00%
register free of charge
|
|
| A rating was issued by 3 analysts: 3 Analysts recommend Marker Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Marker Therapeutics, Inc. stock has an average upside potential 2026 of
716.67%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.59 | 2.97 |
| 99.09% | 54.93% | |
| EBITDA Margin | -168.74% | -427.74% |
| 61.69% | 153.49% |
3 Analysts have issued a sales forecast Marker Therapeutics, Inc. 2025 . The average Marker Therapeutics, Inc. sales estimate is
$3.0m
Unlock
54.93%
lower
Unlock
$5.8m
11.99%
Unlock
$0.0
100.00%
Unlock
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Marker Therapeutics, Inc. 2025 . The average Marker Therapeutics, Inc. EBITDA estimate is
$-12.7m
Unlock
14.24%
lower
Unlock
$-12.7m
14.24%
Unlock
$-12.7m
14.24%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | negative |
Current Marker Therapeutics, Inc. Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WBB Securities |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Ladenburg Thalmann |
Locked
➜
Locked
|
Locked | Oct 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
WBB Securities:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
Ladenburg Thalmann:
Locked
➜
Locked
|
Oct 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
